ClinicalTrials.gg
CompletedNCT01496326ANTIPAINUpdated Dec 21, 2011

Osteoarthritis Topical Treatment

A Phase 2 interventional study of Ibuprofen and placebo in Osteoarthritis, sponsored by BioChemics, Inc.. Completed at 5 sites in Switzerland. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2011-12-21.

Sponsored by BioChemics, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 41 studies in Osteoarthritis with a site in Switzerland — 4 open to participants now, 15 under way, none of them phase 3. Osteoarthritis · Switzerland.

Enrollment
14th of 24
75 · median 85
Started
2011
with 1 other
Phase 2
3 of 41
2 open now
Registered
9th of 41
by date

Among the 41 studies in Osteoarthritis with a site in Switzerland, this one is the 14th largest by enrollment of the 24 interventional ones that give a count, is one of 2 that started in 2011, is one of 3 in phase 2, and was the 9th registered.

Osteoarthritis

2,975 studies on the registry are indexed under Osteoarthritis; 436 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

4 of the 41 studies in Osteoarthritis with a site in Switzerland are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 285 Osteoarthritis studies recruiting now, 157 (55%) set no upper age limit and 71 (25%) stop at 75 or younger; 22 take children under 18; 30 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Osteoarthritis with a site in Switzerland, or all of them as a file.
02

Study summary

This is a phase 2a clinical trial performed to evaluate the efficacy of a topical treatment of ibuprofen compared to the use of a placebo topical treatment.

A multi-center, double-blinded, randomized placebo controlled study. Study length: 14 days Dosing twice daily (b.i.d.)

03

Conditions studied

  • Osteoarthritis

Browse trials for

Keywords

  • Osteoarthritis
  • knee pain
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  • Male or female patients aged at least 40 years.
  • Primary osteoarthritis in a single knee joint, grade II/III based on the Kellgren and Lawrence classification system.
  • Radiographic evidence consistent with osteoarthritis carried out within 6 months before screening.
  • pain is currently not adequately controlled with a simple analgesic or an NSAID OR would necessitate treatment, but is not yet treated.

Main Exclusion Criteria:

  • Concomitant presence of another type of continuous pain that is more severe in intensity in comparison with the osteoarthritis target joint pain
  • Osteoarthritis causing significant pain in any joint other than the identified knee, or contralateral knee (≥ 20 mm pain) as confirmed by a separate VAS at visit 1 for any other painful joint concerned.
  • Female patients who are pregnant or breast-feeding.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
75 participants (actual)

Study arms

  • Experimental
    Ibuprofen

    Drug: Ibuprofen

  • Placebo comparator
    Placebo

    Drug: placebo

Interventions

  • 10% ibuprofen cream formulation at a dose of 200mg

  • Drugplacebo

    2 grams of placebo cream for 14 days

06

What researchers measure

Primary outcomes

  1. Visual Analogue Scale (VAS) Pain scale

    Time frame: 14 days

07

Study locations

5 sites
  • Schaffhausen, 8200, Switzerland
  • St. Gallen, 9000, Switzerland
  • Zürich, 8001, Switzerland
  • Zürich, 8050, Switzerland
  • Rheumaklinik und Institut für Physikalische Medizin Universitätsspital
    Zürich, 8091, Switzerland
08

References and documents

Publications

  • Varadi G, Zhu Z, Blattler T, Hosle M, Loher A, Pokorny R, Frey D, Carter SG. Randomized clinical trial evaluating transdermal Ibuprofen for moderate to severe knee osteoarthritis. Pain Physician. 2013 Nov-Dec;16(6):E749-62. PubMed 24284856 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2011, a primary completion of Aug 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2011
First posted
Dec 21, 2011
Start
Feb 2011
Primary completionActual
Aug 2011
CompletionActual
Aug 2011
Last update
Dec 21, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 21, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01496326
Lead sponsor
BioChemics, Inc.
Responsible party
Sponsor
First posted
Dec 21, 2011
Start date
Feb 2011
Primary completion
Aug 2011
Completion
Aug 2011
Last update
Dec 21, 2011

Study contacts

Stephen Carter, Ph.D.
study director · BioChemics, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibuprofen

Start the discussion